Replacement: Director/PDMR Shareholding

RNS Number : 6638K

MGC Pharmaceuticals Limited

06 May 2022

 

GENERAL TEXT AMENDMENT

The following amendments have been made to the 'Director/ PDMR Shareholding' announcement released on 5^th May 2022 at 11:10am under RNS No 4714K:

1.  Amendment to 4(c) Nature of Transaction: The initial Notice incorrectly described the nature of the transaction as an exercise of Performance Rights granted under an Employee Share Scheme, when in fact the securities were purchased by the director "on market" through a broker. 2.  Amendment to 4(d) Currency: The consideration currency was incorrectly disclosed as AUD, when the consideration paid was in fact GBP.

All other details remain unchanged.

The full amended text is shown below.

MGC Pharmaceuticals Ltd.

PDMR Notifications

06 May 2022

ASX, LSE: MXC

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company'),   a European based bio-pharma company specialising in the production and development of phytomedicines,   wishes to advise that this "amending" notice has been issued to correct 2 errors on the "initial" notice lodged on 5 May 2022 in relation to the recent purchase of MGC shares on the LSE by Dr Stephen Parker, a non-executive director of the Company.

1	Details of the person discharging managerial responsibilities/person closely associated
(a)	Name		Dr Stephen Barry Parker
2	Reason for the notification
(a)	Position		Director
(b)	Initial notification/amendment		amendment
(c)	If amendment: reason		This amending notice has been issued to correct the following errors on the Initial Notice released on 5 May 2022. 3.  Amendment to 4(c) Nature of Transaction: The initial Notice incorrectly described the nature of the transaction as an exercise of Performance Rights granted under an Employee Share Scheme, when in fact the securities were purchased by the director "on market" through a broker. 4.  Amendment to 4(d) Currency: The consideration currency was incorrectly disclosed as AUD, when the consideration paid was in fact GBP.
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
	Full name of entity		MGC Pharmaceuticals Limited
	Legal Entity Identifier Code		213800HRE3FQJ6RK4H10
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
(a)	Description of the financial instrument, type of instrument		Fully Paid Ordinary Shares (DI)
(b)	Identification Code (ISIN)		AU000000MXC6
(c)	Nature of transaction		On market purchase
(d)	Currency	Price		Volume	Total
	GBP	£0.0135		1,111,111	£15,012
	Aggregated information
	GBP	£0.0135		1,111,111	£15,012
(e)	Date of transaction		2022-05-04
(f)	Place of transaction		London Stock Exchange

--Ends--

Authorised for release by the Company Secretary, for further information please contact:

MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director [phone] [e-mail]

MGC Pharmaceuticals Ltd David Lim Company Secretary [phone] [e-mail]

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytomedicines to patients globally.  The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline. 

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.  

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. 

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

 

END

 

 

DSHEALSKEEXAEFA